All In Biotech

Drug Trial Radar · NCT03755700

Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization

Antioxidants for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization

Last checked: Nov 19, 2026Latest source record: Nov 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Nov 1, 2018

Primary completion

Dec 31, 2019

Study completion Dec 31, 2019

Sponsor

Lead sponsor
Rajaie Cardiovascular Medical and Research CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In a double-blinded randomized clinical trial, all patients undergoing coronary artery catheterization who will met our criteria, will be enrolled into three groups to receive either, vitamin e, n-acetylcysteine, or placebo. The aim of study will be to compare the superiority of vitamin e over n-acetylcysteine for the prevention of contrast-induced acute kidney injury (CIAKI).

Conditions

  • Coronary Artery Disease
  • Coronary Artery Angiography
  • Coronary Catheterization
  • Contrast-induced Nephropathy
  • Stable Angina
  • Acute Coronary Syndrome

Interventions

  • Vitamin EDrug

    As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention

  • N-acetyl cysteineDrug

    As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention

  • Placebo oral capsuleDrug

    The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group

  • PlacebosDrug

    The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group

  • Normal Saline Flush, 0.9% Injectable SolutionDrug

    Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Contrast-induced acute kidney injuryTime frame: 48 to 72 hours after coronary catheterization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rajaie cardiovascular medical and research center

    Tehran, Iran · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.